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Infection with varicella-zoster virus (VZV) is common, oc-
curring as primary varicella, usually during childhood, and 
as zoster, following reactivation of latent virus. Although 
serious VZV infections are infrequent, they can be life-threat-
ening when they occur in susceptible immunosuppressed pa-
tients (1, 2). These patients have a high incidence of visceral 
involvement, including pneumonitis, meningoencephalitis, 
and rarely, hepatitis. We report here 3 cases ofVZVhepatitis 
in adult liver transplant recipients that occurred in our in-
stitution between 1984 and 1989. We describe their clinical 
presentations and use these cases to illustrate some aspects 
in diagnosis and prevention ofVZV infection after solid organ 
Tx. 
Case 1. A 19-year-old woman underwent orthotopic liver 
Tx for end-stage liver disease secondary to chronic active 
autoimmune hepatitis. She was receiving prednisone and 
azathioprine before the transplant operation. Her immuno-
suppression after Tx included cyclosporine (CSA) and ste-
roids. At 28 days after her transplant operation, she started 
complaining of low back pain over the coccyx area, but the 
exam of this area did not reveal any skin lesions. Two days 
later she developed few skin vesicles on her face, abdomen, 
and hands. Laboratory examination showed elevation in 
LFTs with serum alanine aminotransferase (AL T) of 196 
IUIL (normal value [nv] <40, IUIL), serum aspartate amino-
transferase lAST) of221 IUIL (nv <40 IUIL) and bilirubin of 
3.5 mg% (nv < 1.0 mg/dD, and gamma GTP of 137 (nv <40 
DILl. On dav 33 after OLTx, her AST increased to 1057 TUIL 
and bilirubi~ increased to 4.7 mg/dL Liver biopsy showed foci 
of coagulative necrosis with minimal mixed inflammatory 
cellular infiltrate and multinucleated cells, with negative 
histochemical stains for HSV 1 and HSV 2. The patient was 
started the same day on intravenous acyclovir at 10 mg/kg 
every 8 hr, but the following day she developed DIC and 
ARDS and expired 37 days after Tx. A blood buffy coat 
specimen was positive subsequently for VZV by culture. IgG 
antibody for VZV was negative on day 33 after OLTx by 
indirect fluorescence assay (IF A). No history of exposure to 
VZV was obtained. 
Case 2. A 33-year-old man underwent a liver and pancreas 
Tx for end-stage liver disease secondary to hepatitis B infec-
tion and hepatoma. Immunosuppression treatment included 
CSA and steroids. His spleen and pancreas and part of his 
colon, duodenum, and stomach were also removed. His im-
mediate postoperative course was complicated by abdominal 
bleeding, renal failure, pancreatitis, and failure of the trans-
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planted graft. He underwent a second liver Tx 7 days after 
the first transplant operation. Then 7 days later (day 14 after 
first Tx) the patient started having daily temperature eleva-
tions to 39.5'C, abdominal pain, and metabolic acidosis. The 
liver function tests showed ALT of 61 lUlL and AST of 68 
TUIL, AP of 265 fUlL, and bilirubin of 21.1 mg/dl. Liver 
biopsy showed coagulative necrosis with mild neutrophilic 
exudate (Fig. 1) and nuclear inclusions were seen (Fig. 2), but 
histochemical stains were negative for HSV 1 and HSV 2. 
The patient's skin examination revealed vesicular lesions on 
the palmar aspect of his hands and also on his neck. He was 
placed on i.v. acyclovir at 10 mg/kg after each dialysis, and 
was also given a dose ofVZIG. Buffy coat and vesicular skin 
lesions samples yielded VZV. 
He remained on a respirator, required hemodialysis, and 
developed bacterial and fungal abdominal sepsis secondary 
to leaks from the bowel. At 31 days after retransplantation 
he required distal pancreatectomy for pancreatic phlegmon. 
He was discharged 5 months after his original transplant 
operation. The patient's blood sample 32 days before Tx 
tested positive for VZV antibodies by IFA, enzyme-linked 
immunoassay (ELISA), and fluorescent-antibody-to-mem-
brane antigen (F MvrA). He denied having had chickenpox in 
the past. Interview of his family members revealed that the 
patient's young nephew was diagnosed with chickenpox 16 
days before his first Tx, and later two of the patient's children 
also contracted this illness. The first child was diagnosed 3 
days before Tx and the second child was diagnosed on the 
same day the patient was electively admitted to the hospital 
for Tx. 
Case 3. A 38-year-old man with chronic active hepatitis B, 
underwent OLTX and was maintained on CSA, prednisone, 
and azathioprine. Nineteen months after his Tx he visited his 
friend's house, and two days later his friend's son, whom he 
met, was diagnosed with chickenpox. The patient was given 
an injection of varicella-zoster immune globulin (VZIG) in-
tramuscularly the day the exposure was reported. Thirty-two 
days after exposure he noticed for the first time malaise and 
the onset of a rash on his chest. He was admitted to the 
hospital with high temperature and vesicular lesions on his 
face, chest, and back. He was started on i.v. acyclovir at 10 
mg/kg every 8 hr and was given an intramuscular injection of 
VZIG. His laboratory tests showed ALT of 824 TUIL, AST of 
2091 TUIL, and bilirubin of 1.0 mg/d!. No liver biopsy was 
performed. A buffy coat culture of blood drawn on admission 
was positive for VZV and IgG varicella antibody titer was 
positive by IF A. A sample of blood prior to his transplant was 
positive with a low titer by IFA. and negative by ELISA and 
F Ai\1A test. The patient was discharged home 12 days after 
admission. 
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FIGURE 1. Focus of coagulative necrosis with surrounding mild neu-
trophilic exudate (H&E: original magnification: x200l. 
Hepatic involvement has been described in childhood vari-
cella, most often subclinically (3), and as hepatitis in immu-
nosuppressed children who develop disseminated disease (J, 
4). In adults, clinical hepatitis may appear in patients with 
varicella pneumonia (5) and sporadically as the only mani-
festation of visceral disease. In the former situation, the 
disease tends to be fatal (6-9>. and to our knowledge, there 
has been only one report of successful treatment with acyclo-
vir therapy (JOL This suggests that V'lV hepatitis is a life-
threatening disease, particularly in the immunocompro-
mised adult host. 
Varicella is reported to cause Reye's syndrome (11, 12), 
making the distinction between this clinical entity and VZV 
hepatitis difficult without a liver biopsy. On the other hand, 
the foci of coagulative necrosis with little inflammatory re-
sponse has been described in both herpes simplex and vari-
cella zoster infections, with varicella often giving smaller and 
better-circumscribed lesions (13,14). Since histology findings 
are similar, it is difficult to distinguish between herpes sim-
plex and varicella hepatitis based on morphology alone, and 
evaluation by immunoperoxidase technique is also needed. It 
was not possible to perfonn specific immunostains for VZV 
because of some technical problems. However, the negative 
FIGURE 2. Intranuclear inclusion body in the periphery of the same 
necrotic area (H&E; original magnification: X400). 
immunostains for HSV 1 and HSV 2 in two patients, along 
with the recovery of VZV from the buffy coats in the three 
patients, suggests that VZV was the cause of the hepatitis. 
Patient 3 did not have liver biopsy and the diagnosis was 
based on liver function test abnonnalities and the recovery of 
V'lV from a buffy coat culture. Although without histology we 
can not really be sure that this patient had hepatitis, VZV 
viremia has been considered as a marker of visceral disease 
in immunocompromised patients (15). 
We have previously reported 12 patients who developed 
herpes simplex hepatitis after solid organ Tx (16). Five of 
these patients developed disseminated intravascular coagu-
lation and expired. This fulminant disease was more common 
in primary infection compared with reactivation, similar to 
the clinical picture of patient 1 in this report. The main 
dissimilarity is that all three patients with varicella hepatitis 
had skin lesions. In our report of herpes simplex hepatitis, 
skin lesions were not common, even in cases with autopsy-
proven disseminated disease to multiple organs (]61. This is 
similar to bone marrow Tx, where higher rates of VZV vis-
ceral dissemination without skin manifestations have been 
reported (] 7). 
In a surveillance perfonned among our adult candidates 
for liver Tx, only 5%: were seronegative for V'lV and therefore 
at risk for infection (unpublished data). Because seronegative 
patients are more susceptible to VZV infection, prophylaxis 
with varicella zoster immunoglobulin NZIG) is recom-
mended for them after virus exposure. However, there are 
conflicting reports regarding its beneficial effect (18). In fact 
some patients given VZIG after exposure to VZV neverthe-
less acquired severe infection (19, 20). On the other hand, 
passive immunity may modify and "mitigate" the disease 
even if not giving an absolute protection. Patient 3 was most 
likely seronegative for VZV before Tx, since the ELISA and 
F AMA tests were negative. The low-positive antibody titer 
detected by IFA may have been related to passive acquisition 
of antibodies through blood transfusion. This patient re-
ceived VZIG one day after exposure; he did contract varicella 
32 days later, with visceral involvement, but survived. Pa-
tient 1 was seronegative for VZV, since serum from day 33 
after Tx tested negative. The exposure in this case was not 
identified and the rash was seen for the first time 28 days 
after the transplant operation. The patient did not receive 
prophylactic treatment and developed a fulminant disease 
with DIe and expired. 
It is assumed that seropositive individuals are not suscep-
tible to varicella. However, there are some reports of immu-
nosuppressed patients who developed varicella more than 
one time (20, 21). Patients may be reinfected with a different 
strain of virus and develop a second episode of varicella (22). 
This is what probably occurred to patient 2, who was sero-
positive before Tx but was exposed to a new virus in the 
familv from his two children and developed varicella with 
hepatitis. The patient might have had disseminated zoster 
secondary to VZV reactivation and not varicella. However, 
his vesicular rash did not follow any dennatomal distribution 
at any time. Moreover, visceral dissemination is not a com-
mon event in dennatomal zoster infection, compared with 
varicella infection (23). The three cases that we reported here 
suggest that transplant recipients in close contact with VZV 
may benefit from VZV prophylaxis, even when the patients 
are seropositive. The question of whether this prophylaxis 
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should be done with VZIG or with oral acyclovir, as recently 
reported in the pediatric population (24, 25) will require 
further investigation. Recently a second oral antiviral agent 
with activity against V'lV, famciclovir. was introduced for 
clinical use, and it may have a role in prophylaxis (26). There 
are some data from leukemic children showing that varicella 
vaccine is both safe and immunogenic in immunocompro-
mised patients (27). Seronegative transplant candidates 
would be good candidates for the use of this vaccine, which 
has recently been released for clinical use. 
Since VZV infection may be life-threatening in solid organ 
transplant patients, and after our experience with these 
three cases, we suggest a tentative management plan for 
prevention of VZV infection in adult transplant recipients. 
These suggestions should be used as a working plan until 
more data are available and conclusive recommendations are 
made regarding the use of passive immunity, antivirals, and 
vaccination in this patient population: 
1. A history of varicella (chickenpox) and zoster (shingles) is 
obtained from all patients during pre-Tx evaluation, and VZV 
IgG titer is checked. (Our laboratory uses ELISA.) Seronega-
tive patients and possibly those with low titer may be candi-
dates for varicella vaccine. 
2. Transplant candidates and recipients are educated to avoid 
exposure to varicella (chickenpox) or zoster (shingles), and to 
immediately report to their nurse coordinators any accidental 
exposure. 
3. After an accidental exposure to V'LV (chickenpox or shingles), 
VZIG is offered to seronegative transplant recipients and 
those with low-positive titer. Varicella-zoster immune globu-
lin I"ZIG> is administered intramuscularly at a dose of 125 
mgllO kg of weight (maximum dose 625 mg). 
4. After any exposure to VZV. susceptible patients should be 
considered for placement on oral acyclovir at 800 mg five times 
a day lor possibly famcyclovir) for the duration of the incuba-
tion period (2-3 weeks). 
5. Development of vesicular skin lesions after exposure should 
prompt viral cultures for herpesvirus (skin lesion and buffy 
coat), and immediate institution of high-dosage acyclovir ther-
apy (10 mglkg every 8 hr. i.v.) while awaiting confirmation of 
diagnosis. 
6. Liver function tests abnormalities in a patient who has had a 
recent exposure to VZV should prompt liver biopsy. 
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